Economic Evaluation of Heart Failure Management in Colombian Clinics (EconoHeart)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: March 9, 2010
Last updated: NA
Last verified: March 2010
History: No changes posted

Cost effectiveness analysis of local management of patients diagnosed with heart failure disease compared with an ideal guideline-based management.

Heart Failure

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Economic Evaluation of Heart Failure Management in Colombian Clinics

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To determine cost-effectiveness of Heart Failure management in 3 Heart-specialized clinics in Bogotá Colombia [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Incremental cost-effectiveness ratio from using Symbicort as symbicort as Maintenance and Reliever Therapy (SMART) when compared with its competitive alternatives [ Designated as safety issue: No ]

Enrollment: 300
Study Start Date: January 2008
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
moderate to severe uncontrolled asthma


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Moderate to severe uncontrolled asthma.


Inclusion Criteria:

  • Asthma moderate to severe.
  Contacts and Locations
Please refer to this study by its identifier: NCT01084564

Sponsors and Collaborators
Study Director: Rodolfo Dennis, M.D. Pontificia Universidad Javeriana
Principal Investigator: MARÍA XIMENA ROJAS, M.D. Pontificia Universidad Javeriana
  More Information

No publications provided

Responsible Party: MC MD, AstraZeneca Identifier: NCT01084564     History of Changes
Other Study ID Numbers: NIS-CCO-ATA-2007/1
Study First Received: March 9, 2010
Last Updated: March 9, 2010
Health Authority: Colombia: Institutional Review Board

Keywords provided by AstraZeneca:
Cost-effectiveness analysis

Additional relevant MeSH terms:
Heart Failure
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Heart Diseases
Cardiovascular Diseases processed this record on April 15, 2014